Combining TACE with Atezolizumab and Bevacizumab for Unresectable Liver Cancer
Atezolizumab Plus Bevacizumab Plus Transarterial Chemoembolization and Hepatic Artery Infusion Chemotherapy for Unresectable Advanced Hepatocellular Carcinoma: a Single-arm Phase 2 Clinical Trial
This study is testing whether a new treatment that combines a type of chemotherapy with two immunotherapy drugs can help people with liver cancer that can't be surgically removed feel better compared to current treatments.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 55 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | atezolizumab, bevacizumab, chemotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT05751343 on ClinicalTrials.gov |
What this trial studies
This phase 2 clinical trial investigates the effectiveness of combining transarterial chemobolization (TACE) with hepatic artery infusion chemotherapy and the immunotherapy drugs atezolizumab and bevacizumab in patients with unresectable hepatocellular carcinoma (HCC). The study aims to determine whether this combination improves the objective response rate compared to existing treatments. Eligible participants will be closely monitored for their response to the treatment regimen, which includes both chemotherapy and immunotherapy components.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with unresectable hepatocellular carcinoma and with Child-Pugh A or B liver function.
Not a fit: Patients with severe underlying cardiac, pulmonary, or renal diseases, or those with contraindications to atezolizumab and bevacizumab may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes for patients with unresectable HCC.
How similar studies have performed: While the combination of TACE with immunotherapy is a novel approach, similar studies have shown promising results in other cancer types, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * (a) patients were diagnozied with unresectable advanced-stage HCC, * (b) Child-Pugh A or B liver function; * (d) Eastern Cooperative Oncology Group (ECOG) performance status 0-1; * (e) adequate hematologic blood counts (white blood cell count \>3ⅹ109/L, absolute neutrophil count \>1.5ⅹ109/L, platelet count \>10ⅹ109/L, hemoglobin concentration \>85 g/L); Exclusion Criteria: * (a) severe underlying cardiac, pulmonary, or renal diseases; * (b) history of a second primary malignant tumor; * (c) contraindication to either atezolizumab and bevacizumab.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.